4.3 Review

Chromophobe renal cell carcinoma: A review of an uncommon entity

Journal

INTERNATIONAL JOURNAL OF UROLOGY
Volume 19, Issue 10, Pages 894-900

Publisher

WILEY
DOI: 10.1111/j.1442-2042.2012.03079.x

Keywords

chromophobe renal cell carcinoma; metastatic renal cell carcinoma; mammalian target of rapamycin inhibitors; renal cell carcinoma; tyrosine kinase inhibitors

Ask authors/readers for more resources

Renal cell carcinoma is the most common neoplasm of the kidney. It is a heterogeneous disease, comprised of different histological variants with a distinct clinical course, genetics and response to treatment. The various subtypes identified include clear cell, papillary and chromophobe, among others. Chromophobe renal cell carcinoma is a rare variant and accounts for 5% of all cases. These tumors are macroscopically larger when compared with other forms and are commonly diagnosed at an early stage. Despite significant advances in renal cell carcinoma therapeutics in the past decade, no standard treatment has been identified for advanced chromophobe renal cell carcinoma. Nevertheless, new molecular insights have recently become available. A familial form of renal cell carcinoma, the BirtHoggDube syndrome, has been described and the knowledge obtained has opened research opportunities in the therapeutic arena of chromophobe renal cell carcinoma. The following manuscript will endeavor to provide an overview of this uncommon entity including pathology, epidemiology, genetics, clinical aspects, and current and future treatment options.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available